Drug & intervention

ofatumumab

RxCUI 712566

Clinical trials26
Recruiting1
Related conditions19
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

26 shown
Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) LevelsNCT07353216 · 2023-12-01
RECRUITING
Switch to Ofatumumab and Level of ImmunoglobulinsNCT07625800 · 2026-06-01
NOT_YET_RECRUITING
An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of CD20 Monoclonal Antibody Combined With NK042 Cell Injection in the Treatment of Multiple Sclerosis (MS).NCT07546110 · 2026-05-01
NOT_YET_RECRUITING
ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS PatientsNCT06345157 · 2024-07-30
ACTIVE_NOT_RECRUITING
WOE of Anti-CD20 TherapiesNCT06121349 · 2023-12-04
COMPLETED
Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking OfatumumabNCT06167642 · 2023-05-22
ENROLLING_BY_INVITATION
Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating DiseasesNCT05414487 · 2022-10-15
UNKNOWN
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) ElevationNCT05090371 · 2022-03-02
ACTIVE_NOT_RECRUITING
Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab TreatmentNCT05171972 · 2022-01-29
COMPLETED
Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.NCT05084638 · 2022-01-25
COMPLETED
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple SclerosisNCT04926818 · 2021-10-05
ACTIVE_NOT_RECRUITING
Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMSNCT04788615 · 2021-07-23
COMPLETED
A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With OfatumumabNCT04878211 · 2021-06-10
TERMINATED
Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With OfatumumabNCT04869358 · 2021-05-27
COMPLETED
Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple SclerosisNCT04676555 · 2021-05-11
COMPLETED
A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With OfatumumabNCT04667117 · 2021-01-14
COMPLETED
A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple SclerosisNCT04486716 · 2020-10-19
COMPLETED
9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple SclerosisNCT04510220 · 2020-09-21
COMPLETED
Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label OfatumumabNCT03249714 · 2018-03-15
COMPLETED
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaNCT01578707 · 2012-06-01
COMPLETED
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic LeukemiaNCT01313689 · 2011-04-14
COMPLETED
Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic LeukemiaNCT00742144 · 2008-09-19
COMPLETED
Study to Evaluate SC Route of Administration of Ofatumumab in RA PatientsNCT00686868 · 2008-06-13
COMPLETED
Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist TherapyNCT00603525 · 2008-01-01
TERMINATED
Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to MTX TherapyNCT00611455 · 2008-01-01
TERMINATED
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403NCT00655824 · 2008-01-01
TERMINATED

Conditions being studied

Multiple Sclerosis7Relapsing Multiple Sclerosis5Arthritis, Rheumatoid4Demyelinating Diseases of the Central Nervous System1Leukaemia1Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular1Multiple Sclerosis (MS)1Multiple Sclerosis, Relapsing-Remitting1Neuromyelitis Optica Spectrum Disorder1Relapse Remitting Multiple Sclerosis1Relapsed or Refractory Chronic Lymphocytic Leukemia1Relapsing Forms of Multiple Sclerosis1Relapsing Multiple Sclerosis (RMS)1Relapsing Remitting Multiple Sclerosis1Relapsing-Remitting Multiple Sclerosis1Retinal Degeneration1Small Lymphocytic Lymphoma1Tomography, Optical Coherence1Visual Acuity1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.